Cardiff Oncology, Inc.CRDFNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +17.02% | -3.21% | -46.83% | -25.77% | -27.27% |
| Gross Profit Growth | -27967.65% | +184.91% | +5.83% | -19856.90% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +4.90% | +6.65% | +48.90% | +48.41% | +42.71% |
| Weighted Average Shares Diluted Growth | +4.90% | +6.65% | +6.65% | +48.41% | +42.71% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +212.12% | +168.40% | +3.05% | +16.63% | -58.90% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -28.89% | +19.05% | +14.55% | +14.67% | +1.41% |
| Book Value per Share Growth | -39.50% | +11.52% | -21.83% | -24.62% | -30.78% |
| Debt Growth | -26.54% | -29.13% | -32.10% | -35.70% | -40.09% |
| R&D Expense Growth | +20.17% | +25.11% | +30.83% | +21.98% | -14.97% |
| SG&A Expenses Growth | -100.00% | +10.50% | +32.56% | -100.00% | +0.00% |